MX2013006361A - Agtr1 como marcador para terapias combinadas de bevacizumab. - Google Patents

Agtr1 como marcador para terapias combinadas de bevacizumab.

Info

Publication number
MX2013006361A
MX2013006361A MX2013006361A MX2013006361A MX2013006361A MX 2013006361 A MX2013006361 A MX 2013006361A MX 2013006361 A MX2013006361 A MX 2013006361A MX 2013006361 A MX2013006361 A MX 2013006361A MX 2013006361 A MX2013006361 A MX 2013006361A
Authority
MX
Mexico
Prior art keywords
patient
bevacizumab
treatment
proliferative disorder
agtr1
Prior art date
Application number
MX2013006361A
Other languages
English (en)
Inventor
La Haba-Rodriguez Juan De
Pedro Sanchez-Rovira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013006361A publication Critical patent/MX2013006361A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención provee métodos para determinar la responsividad o sensibilidad de un paciente a un inhibidor de angiogénesis tal como un agente de enlace de VEGF, particularmente bevacizumab (Avastin(r)), ya sea solo o en combinación con un régimen de quimioterapia, al determinar el nivel de expresión del receptor de angiotensina II tipo 1 (AGTR1) en relación con un nivel de control determinado en pacientes que sufren de una alteración proliferativa. En particular, la presente invención es concerniente con un método para la identificación de un paciente responsivo o sensible al tratamiento con bevacizumab, dicho paciente es sospechoso de sufrir de o es propenso de sufrir una alteración proliferativa, en donde el método comprende la etapa de determinar el nivel de expresión del receptor de angiotensina II tipo 1 (AGTR1) en una muestra biológica de dicho paciente, en donde un nivel de expresión incrementado de AGTR1, en comparación con un nivel de control determinado en pacientes que sufren de cáncer, es indicador de que dicho paciente será responsivo o sensible al tratamiento con bevacizumab. La presente invención también provee una composición que comprende un inhibidor de angiogénesis tal como un agente de enlace de VEGF, particularmente bevacizumab (Avastin(r)), para uso en el tratamiento de una alteración proliferativa en un paciente identificado por el método provisto y revelado en la presente, el uso de un inhibidor de angiogénesis tal como un agente de enlace de VEGF, particularmente bevacizumab (Avastin(r)), para la preparación de una composición farmacéutica para el tratamiento de una alteración proliferativa en un paciente identificado por el método provisto y revelado en la presente, también como por métodos para el tratamiento de una alteración proliferativa que comprende administrar una cantidad efectiva de un inhibidor de angiogénesis tal como un agente de enlace de VEGF, particularmente bevacizumab (Avastin(r)) a un sujeto identificado por el método provisto y revelado en la presente.
MX2013006361A 2010-12-09 2011-12-07 Agtr1 como marcador para terapias combinadas de bevacizumab. MX2013006361A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194391 2010-12-09
EP10382332 2010-12-09
PCT/EP2011/072026 WO2012076582A1 (en) 2010-12-09 2011-12-07 Agtr1 as a marker for bevacizumab combination therapies

Publications (1)

Publication Number Publication Date
MX2013006361A true MX2013006361A (es) 2013-07-30

Family

ID=45420590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006361A MX2013006361A (es) 2010-12-09 2011-12-07 Agtr1 como marcador para terapias combinadas de bevacizumab.

Country Status (10)

Country Link
US (1) US20140030257A1 (es)
EP (1) EP2649451A1 (es)
JP (1) JP2014501918A (es)
KR (1) KR20130124961A (es)
CN (1) CN103339508A (es)
BR (1) BR112013014195A2 (es)
CA (1) CA2819080A1 (es)
MX (1) MX2013006361A (es)
RU (1) RU2013131168A (es)
WO (1) WO2012076582A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
WO2015119362A1 (ko) * 2014-02-07 2015-08-13 아주대학교산학협력단 Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물, rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법
CN104195231B (zh) * 2014-07-24 2017-01-18 益善生物技术股份有限公司 贝伐单抗疗效相关基因表达检测液相芯片试剂盒
SG11201703744VA (en) * 2014-11-14 2017-06-29 Genentech Inc Predicting response to a vegf antagonist
ES2925002T3 (es) * 2015-11-11 2022-10-13 Navifus Co Ltd Método y kit para el tratamiento de tumor cerebral mediante el uso del sistema de ultrasonidos
EP3447143A4 (en) 2016-04-19 2019-11-20 Toppan Printing Co., Ltd. ANTICANCER DRUG EVALUATION METHOD
WO2021142253A1 (en) * 2020-01-10 2021-07-15 President And Fellows Of Harvard College Anti-angiotensin ii type 1 receptor (agtr1) binding proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
GB0207362D0 (en) * 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
MXPA06013997A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con oxaliplatino y un inhibidor de la quinasa del receptor del factor de crecimiento epidermal (egfr).
US20080207714A1 (en) * 2006-11-09 2008-08-28 The Regents Of The University Of Michigan Diagnosis And Treatment Of Breast Cancer
WO2008121402A1 (en) * 2007-03-30 2008-10-09 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative diseases
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer

Also Published As

Publication number Publication date
BR112013014195A2 (pt) 2017-08-15
JP2014501918A (ja) 2014-01-23
CN103339508A (zh) 2013-10-02
EP2649451A1 (en) 2013-10-16
CA2819080A1 (en) 2012-06-14
KR20130124961A (ko) 2013-11-15
RU2013131168A (ru) 2015-01-20
WO2012076582A1 (en) 2012-06-14
US20140030257A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2013006361A (es) Agtr1 como marcador para terapias combinadas de bevacizumab.
NZ603780A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
MX2013012183A (es) Terapia de combinacion de hsp90.
WO2011015602A3 (en) Lung cancer biomarkers
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
NZ606495A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
NZ612483A (en) Drug selection for malignant cancer therapy using antibody-based arrays
MY172580A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
MX2015000684A (es) Metodo para detectar cancer.
MX357292B (es) Método para detectar cáncer.
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2015013508A3 (en) Methods for diagnosing and treating immune disease